ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2024
Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study.
Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Definitions of early COPD and predictors for disease progression: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Seeing is believing-on the utility of CT in phenotyping chronic obstructive pulmonary disease.The British journal of radiology · 2026Review
- Mapping the trajectory from pre-COPD to COPD: predictive value of symptoms, imaging, and physiologic abnormalities.Annals of the American Thoracic Society · 2026Article
- Pre-COPD: Impact on prevention, detection, and treatment.Presse medicale (Paris, France : 1983) · 2026Review
- Small Airway Disease in Pre-COPD and Early COPD: Insights Into the Pulmonary "Silent Zone".International journal of chronic obstructive pulmonary disease · 2026Review
- Analytical validation of total mucin concentration assay using SEC MALLS dRI for diagnosing and monitoring mucoobstructive lung diseases.Scientific reports · 2025Article
- Lung Volumes in Smokers without Chronic Obstructive Pulmonary Disease: A Pointer to Disease Development?Annals of the American Thoracic Society · 2025Article
- Observational studies of exposure to tobacco and nicotine products: Best practices for maximizing statistical precision and accuracy.iScience · 2025Review
- Lung Health of Early COPD (LHEC): A Multi-Center Cohort Study-Rational and Design.International journal of chronic obstructive pulmonary disease · 2025Article
- Demographic and Clinical Characteristics of Mild, Young and Early COPD: A Cross-Sectional Analysis of 5468 Patients.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
Abstract
Background: The biological mechanisms leading some tobacco-exposed individuals to develop early-stage chronic obstructive pulmonary disease (COPD) are poorly understood. This knowledge gap hampers development of disease-modifying agents for this prevalent condition. Objectives: Accordingly, with National Heart, Lung and Blood Institute support, we initiated the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) Study of Early COPD Progression (SOURCE), a multicenter observational cohort study of younger individuals with a history of cigarette smoking and thus at-risk for, or with, early-stage COPD. Our overall objectives are to identify those who will develop COPD earlier in life, characterize them thoroughly, and by contrasting them to those not developing COPD, define mechanisms of disease progression. Methods/Discussion: SOURCE utilizes the established SPIROMICS clinical network. Its goal is to enroll n=649 participants, ages 30-55 years, all races/ethnicities, with ≥10 pack-years cigarette smoking, in either Global initiative for chronic Obstructive Lung Disease (GOLD) groups 0-2 or with preserved ratio-impaired spirometry; and an additional n=40 never-smoker controls. Participants undergo baseline and 3-year follow-up visits, each including high-resolution computed tomography, respiratory oscillometry and spirometry (pre- and postbronchodilator administration), exhaled breath condensate (baseline only), and extensive biospecimen collection, including sputum induction. Symptoms, interim health care utilization, and exacerbations are captured every 6 months via follow-up phone calls. An embedded bronchoscopy substudy involving n=100 participants (including all never-smokers) will allow collection of lower airway samples for genetic, epigenetic, genomic, immunological, microbiome, mucin analyses, and basal cell culture. Conclusion: SOURCE should provide novel insights into the natural history of lung disease in younger individuals with a smoking history, and its biological basis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.